The technology will be able to make tiny pills that will heal and no longer require an eye to be examined, says Ralf Köhler, the chief medical officer of the German drugmaker Pfizer.

In the future, he says, it could be able deliver drugs in a matter of seconds.

The company, which is trying to develop an eye-tracking drug, announced last month it had acquired Ocularo, a company that makes self-taping pill dispensing devices for eye health and eye protection.

Köhl is also the CEO of a startup called Aeon Therapeutics, which specializes in developing eye-sensing drugs for use in the developing world.

He says he’s not looking to make any immediate money from the deal, but he hopes to eventually use the technology to deliver medicine to people with blindness.

He predicts it will be used to treat blindness from diabetes and other conditions, and to treat eye diseases such as cataracts and retinal detachment.

The company’s eye-catching technology could be applied to eyewear, eyewashes, or any other consumer product, he adds.

Kähler says he plans to work with Ocularos founders to get the company off the ground and has already secured financing from two private equity firms.

But it’s not clear how much the deal will be worth.

“I’ve been asked to estimate the total cost of the business, but that will probably be in the tens of millions of euros,” Köls said.

He added that he is looking forward to a big leap forward in technology and the use of Oculars technology.

Ocularos says it is targeting its drug, called Ligaripron, for people with severe cataract damage and the elderly.

It has raised $1.5 million from German and U.S. investors and expects to begin commercial sales in 2019.